Sichuan Hebang Biotechnology Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Huirong Yang

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	7yrs
CEO ownership	0.002%
Management average tenure	12.1yrs
Board average tenure	7.5yrs

Recent management updates

Recent updates

Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?

Mar 07

Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock

Apr 21

CEO

Huirong Yang (57 yo)

7yrs

Tenure

CN¥931,400

Compensation

Ms. Huirong Yang has been the General Manager of Sichuan Hebang Biotechnology Corporation Limited since May 25, 2017 and served as its Supervisor since March 2011 until May 25, 2017.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Huirong Yang	General Manager	7yrs	CN¥931.40k	0.0024% CN¥ 419.9k
Jun Wang	CFO, Deputy GM & Director	16.3yrs	CN¥706.60k	0.036% CN¥ 6.2m
Rong Mo	Secretary & Director	16.3yrs	CN¥725.00k	0.036% CN¥ 6.2m
Anping Liu	Deputy General Manager	8yrs	CN¥382.30k	no data

12.1yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 603077's management team is seasoned and experienced (12.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jun Wang	CFO, Deputy GM & Director	16.3yrs	CN¥706.60k	0.036% CN¥ 6.2m
Rong Mo	Secretary & Director	16.3yrs	CN¥725.00k	0.036% CN¥ 6.2m
Changhua Yuan	Independent Director	4yrs	no data	no data
Zhenggang He	Director	16.3yrs	CN¥1.04m	4.99% CN¥ 866.5m
Hongwu Yang	Director	11.3yrs	CN¥217.70k	0.035% CN¥ 6.1m
Chengyun Miao	Chairman of the Supervisory Board	16.3yrs	no data	no data
Xiaoping Zeng	Chairman	8yrs	CN¥1.13m	no data
Shuxian Mei	Independent Director	7yrs	no data	no data
Changhua Yuan	Independent Director	4yrs	CN¥100.00k	no data
Xueling Qin	Director	3yrs	CN¥100.00k	0.000050% CN¥ 8.7k
Yang Hu	Independent Director	4yrs	CN¥100.00k	no data
Rongpeng Gong	Employee Representative Supervisor	7yrs	no data	no data

7.5yrs

Average Tenure

58yo

Average Age

Experienced Board: 603077's board of directors are considered experienced (7.5 years average tenure).

Sichuan Hebang Biotechnology Management

Management criteria checks 2/4

Key information

Recent management updates

Sichuan Hebang Biotechnology Corporation Limited, Annual General Meeting, May 15, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Sichuan Hebang Biotechnology Corporation Limited, Annual General Meeting, May 15, 2024

First quarter 2024 earnings released: EPS: CN¥0.004 (vs CN¥0.046 in 1Q 2023)

Sichuan Hebang Biotechnology Corporation Limited to Report Q1, 2024 Results on Apr 27, 2024

Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 400 million worth of its shares.

Sichuan Hebang Biotechnology Corporation Limited to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.046 (vs CN¥0.092 in 3Q 2022)

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 400 million worth of its shares.

Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) announces an Equity Buyback for CNY 400 million worth of its shares.

New minor risk - Profit margin trend

Sichuan Hebang Biotechnology Corporation Limited to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: EPS: CN¥0.046 (vs CN¥0.12 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.36 in FY 2021)

Price target increased to CN¥6.00

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.092 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.078 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.03 loss in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.078 (vs CN¥0.009 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.004 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.005 (vs CN¥0.06 in FY 2019)

New 90-day high: CN¥1.57

New 90-day low: CN¥1.32

New 90-day low: CN¥1.33

New 90-day high: CN¥1.52

Third quarter earnings released

New 90-day low: CN¥1.34

SichuanHebang Biotechnology Co.,Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day high - CN¥1.63

First half earnings released

New 90-day high - CN¥1.48

SichuanHebang Biotechnology Co.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age